In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clea...
Nacionales
LITERAL 2 MIN LECTURAIn the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clea...
Compártela con tus amigos y mantén a otros informados.
Inclinación Política
Postmedia
Inclinación Política
Postmedia
USD
EUR
Recibe cada mañana las 5 noticias que debes saber, analizadas por nuestra inteligencia artificial.
Suscribirme gratis
USD
EUR
